Subcutaneous Drug Development & Delivery Consortium Inc
- Assets
- $901.2k
- Revenue
- $760.0k
- Investments
- $0.0
- Employees
- 0
- Location
- Beaverton, OR
- Founding
- Data as of
- 12/2023
- EIN
- 85-0837695
Organization Overview
Subcutaneous Drug Development & Delivery Consortium Inc is located in Beaverton, OR. According to its NTEE Classification (S46) the organization is classified as: Boards of Trade, under the broad grouping of Community Improvement & Capacity Building and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Subcutaneous Drug Development & Delivery Consortium Inc is a 501(c)(6) and as such, is described as a "Business League, Chambers of Commerce, or Real Estate Board" by the IRS.
For the year ending 12/2023, Subcutaneous Drug Development & Delivery Consortium Inc generated $760.0k in total revenue. This organization has experienced exceptional growth, as over the past 4 years, it has increased revenue by an average of 11.0% each year . All expenses for the organization totaled $769.2k during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
OUR MISSION IS TO COLLABORATIVELY ADVANCE THE MOST PRESSING ISSUES AND OPPORTUNITIES IN SUBCUTANEOUS DOSAGE AND DELIVERY IN A PRECOMPETITIVE MANNER.
Describe the Organization's Program Activity:
Part 3 - Line 4a
BIOAVAILABILITY COLLABORATIVE RESEARCH PROJECT: "BIOAVAILABILITY PREDICTION BASED ON PBPK MODELING LEVERAGING DATA OBTAINED VIA OPEN FLOW MICROPERFUSION (OFM) TECHNOLOGY" FIRST RFP FOR SC CONSORTIUM TRANSLATED TO COLLABORATION WITH JOANNEUM/ BIONOTUS - IN-VIVO STUDIES COMPLETED AND PRELIMINARY MODEL HAS BEEN DEVELOPED; SHARED KEY LEARNINGS INCLUDING LEGAL FRAMEWORK FOR FUTURE RFPS; TECHNOLOGY AREAS SCOUTED TO FOCUS SCOPE OF FUTURE RFPS.
HIGH DOSE HIGH VOLUME: "TOWARDS MORE TOLERABLE SUBCUTANEOUS ADMINISTRATION: REVIEW OF CONTRIBUTING FACTORS FOR IMPROVING COMBINATION PRODUCT DESIGN" COMPLETION OF LITERATURE SEARCH AND LANDSCAPE OF HDHV PAIN KNOWLEDGE; DRAFTED A MANUSCRIPT REVIEWING SC PAIN ON INJECTION FOR HIGH DOSE AND HIGH VOLUME DRUGS; IDENTIFIED GAPS AND MADE RECOMMENDATIONS FOR FUTURE SC PRODUCT DESIGN.
PATIENT PREFERENCE AND EXPERIENCE: COMPLETED COMPREHENSIVE DRAFT OF MANUSCRIPT, SUMMARIZING THE PATIENT TREATMENT JOURNEY STARTING AT DIAGNOSIS, INCLUDING CONSIDERATION OF PATIENT CHARACTERISTICS AND SC PRODUCT DESIGN ATTRIBUTES TO INFORM SC DRUG DELIVERY DESIGN AND DEVELOPMENT. THE MANUSCRIPT ALSO OFFERS FUTURE PERSPECTIVES TO FILL DATA GAPS TO ADVANCE PATIENT-CENTRIC SC DRUG DELIVERY. INITIATED CONVERSATIONS AROUND THE NEXT PRIORITIES, GAINING AGREEMENT TO PRIORITIZE ADDITIONAL PATIENT RESEARCH.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Donna French President | OfficerTrustee | 5 | $0 |
Sachin Mittal Vice Preside | OfficerTrustee | 5 | $0 |
David Kang Treasurer | OfficerTrustee | 5 | $0 |
Monica Adams Director | Trustee | 5 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Vital Technical Marketing Inc Management | 12/30/23 | $311,130 |
Charles River Associates Management | 12/30/23 | $225,000 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $0 |
| Total Program Service Revenue | $760,000 |
| Investment income | $0 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $760,000 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $311,130 |
| Fees for services: Legal | $15,904 |
| Fees for services: Accounting | $2,014 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $406,110 |
| Advertising and promotion | $0 |
| Office expenses | $619 |
| Information technology | $1,283 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $32,139 |
| Insurance | $0 |
| All other expenses | $0 |
| Total functional expenses | $769,199 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $564,090 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $337,136 |
| Other assets | $0 |
| Total assets | $901,226 |
| Accounts payable and accrued expenses | $275,722 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $275,722 |
| Net assets without donor restrictions | $625,504 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $901,226 |